Share on StockTwits

Aratana Therapeutics (NASDAQ:PETX) announced its earnings results on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01, StockRatingsNetwork reports. The company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.09 million. The company’s revenue for the quarter was up NaN% on a year-over-year basis.

Aratana Therapeutics (NASDAQ:PETX) traded down 1.30% on Tuesday, hitting $12.19. 214,065 shares of the company’s stock traded hands. Aratana Therapeutics has a 1-year low of $6.56 and a 1-year high of $29.32. The stock has a 50-day moving average of $15.07 and a 200-day moving average of $18.54. The company’s market cap is $359.3 million.

A number of research firms have recently commented on PETX. Analysts at Zacks downgraded shares of Aratana Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, April 14th. They now have a $18.40 price target on the stock. On the ratings front, analysts at Jefferies Group initiated coverage on shares of Aratana Therapeutics in a research note on Monday, March 24th. They set a “buy” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $30.57.

In other Aratana Therapeutics news, Insider Ernst Heinen sold 10,000 shares of Aratana Therapeutics stock on the open market in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $13.42, for a total value of $134,200.00. Following the completion of the sale, the insider now directly owns 95,294 shares of the company’s stock, valued at approximately $1,278,845. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.